Related Experiment Video
Updated: Apr 17, 2026

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
Published on: October 3, 2019
[Successful drug desensitization after vemurafenib-induced rash]
N Klossowski1, A Kislat, B Homey
1Hautklinik, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Abstract:
The BRAF inhibitor vemurafenib was approved in 2011 for the treatment of inoperable or metastatic melanoma. Vemurafenib therapy is associated with several side effects, such as arthralgia, secondary skin tumors or inflammatory rashes. In particular cutaneous toxicities represent a serious threat to patients' adherence. Here, we present the case of a successful drug desensitization in a patient that presented with a vemurafenib-induced rash. Lymphocyte activation tests failed to detect drug-specific T cells, suggesting that the development of the rash was based upon a nonallergic drug hypersensitivity reaction. A program of slow desensitization was initiated and subsequently, vemurafenib was tolerated at the full effective and recommended dosage.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Allergic Drug Reactions
Drug toxicity: Idiosyncratic Reactions
Desensitization and Tachyphylaxis
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
